Arbutus receives authorization to proceed with an investigational new drug application (ind) for ab-729, its proprietary subcutaneously-delivered rnai agent

Phase 2a trial to investigate the safety and anti-viral activity of ab-729 in combination with ongoing nucleos(t)ide analog (na) therapy and short courses of peg-ifnΑ-2a in subjects with chronic hepatitis b virus infection (chb)
ABUS Ratings Summary
ABUS Quant Ranking